RE: Arm 23 Feb 2024 08:09
From 13th December:
4. The next steps with AVA6000 involve optimising the patient population, dose and schedule in order to increase efficacy and tolerability of doxorubicin treatment via pre|CISIONTM targeting. Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.
Anyone know what has happened since then have Avacta found the patients they need and started the fortnightly dosing. When can we expect some next news?